The short version
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Acyclovir
Acyclovir · ACYCLOVIR 50 mg/g · Cream · Topical · Zydus Lifesciences Limited
NDC 70771-1808-02 · 1 TUBE in 1 CARTON / 2 g in 1 TUBE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 45802-0044-75) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$13.26per unit
middle half $11.53–$34.78 · 171 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $13.26
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
3%of plans cover it
tier 4 · prior auth 1% · step therapy 0% · qty limit 86%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for acyclovir (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA206770
- TE code
- BX
- Approval date
- Feb 28, 2023
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Acyclovir (Cream)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alembic Pharmaceuticals Inc. | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals LLC | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Bausch Health US, LLC | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Padagis Israel Pharmaceuticals Ltd | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Viona Pharmaceuticals Inc | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | ACYCLOVIR 50 mg/g | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Acyclovir — NDC 70771-1808-02," retrieved September 3, 2026, https://drugdashboards.com/drug/70771180802.
Free to cite with attribution — see how the data is put together.